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Purpose: Radiation therapy is the standard treatment for symptomatic bone metastases. Several
randomized control trials and meta-analyses have concluded a similar efﬁcacy in pain relief when
comparing single versus multiple fraction regimes. However, there continues to be reluctance to
conform to published guidelines that recommend a single treatment for the palliation of painful bone
metastases. The purpose of this literature review is to summarize international patterns of practice, and
to determine if guidelines recommending single fraction treatment have been implemented in clinical
care.Methods: A literature search was conducted in Ovid Medline, Embase, and Cochrane Central. Search
words included, ‘bone metastases’, ‘radiation therapy’, ‘radiotherapy’, ‘patterns of practice’, and ‘dose
fractionation’. Both prospective and retrospective studies that investigated the prescription of radio-
therapy to bone metastases using actual patient databases were included. Articles were excluded if they
investigated hypothetical scenarios. Results: Six hundred and thirteen results were generated from the
literature search. Twenty-six articles met the inclusion criteria. Of these, 11 were Canadian, 8 were
European, 6 were American, and 1 was Australian. The use of single fraction radiotherapy (SFRT) ranged
from 3% to 75%, but was generally lower in American studies. Choice of fractionation depended on a
variety of factors, including patient age, prognosis, site of irradiation, and physician experience.
Conclusion: Despite the publication of robust randomized control trials, meta-analyses, and clinical
practice guidelines recommending the use of a single treatment to palliate uncomplicated bone
metastasis, SFRT is internationally underutilized.
& 2014 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Bone metastases are a common event in metastatic cancer and
are a signiﬁcant cause of morbidity that can lead to pain,
hypercalcaemia, pathologic fracture, spinal cord compression,
and reduction in quality of life (QOL) [1]. The prevalence in
metastatic breast and prostate cancer patients is as high as 70–
90% at autopsy [1,2]. In patients with bone metastases, goals of
care often surround pain management and maintenance or
improvement of QOL [3]. A variety of treatment modalities are
utilized in a multidisciplinary fashion in order to achieve this goal.
This includes analgesia, bone modifying agents such as bispho-
sphonates, and radiation therapy (RT) [3,4]. Where analgesic
medications frequently result in side effects like constipation and
dry mouth, radiation therapy is well tolerated with fewer side
effects and provides signiﬁcant pain relief in approximately 70% of
patients [5]. Furthermore, RT has been shown to help prevent
subsequent skeletal related events associated with bone metas-
tases and improve overall QOL [6].
Many dose fractionation options exist in the palliation of
symptomatic bone metastases, with the most common fractiona-
tion schedules being a single 8 Gy in one fraction, 20 Gy in ﬁve
fractions, and 30 Gy in ten fractions [7]. Numerous randomized
control trials (RCTs) have concluded that both single fraction
radiation therapy (SFRT) and multiple fraction radiation therapy
(MFRT) are efﬁcacious in providing pain relief caused by uncom-
plicated bone metastases [4,7]. MFRT may be indicated in the
treatment of complicated bone metastases, such as those causing
neuropathic pain, pathologic fractures, or spinal cord compression
[8,9]. As such, guidelines from the American Society for Radiation
Oncology (ASTRO) and the American College of Radiology (ACR)
recommend SFRT as the preferred treatment for uncomplicated
bone metastases [10,11].
Despite these evidence based guidelines, studies have shown
that there is a reluctance to implement them into current practice
[7,12]. Many of these studies are survey-based asking physicians
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about fractionation schedules of choice regarding hypothetical
scenarios [12,13]. Conclusions from these studies may overesti-
mate the prevalence of SFRT due to their survey based methodol-
ogies. Our review focussed on studies that have investigated actual
patient databases with the goal being to present a more accurate
assessment of international patterns of practice over the past
twenty years, particularly with respect to the use of SFRT.
2. Methods
A literature search was conducted using OvidSP Medline (1946 –
Week 4 2014), Embase (1947 – Week 5 2014), and the Cochrane
Central Register of Controlled Trials (Dec 2013) databases. A search
was also conducted in the bibliographies of chosen articles as well as
in the ASTRO 2014 book of published abstracts. The search was limited
to English and restricted to those published after 1994. Subject
headings and keywords used included ‘bone metastases’, ‘radiation
therapy’, ‘radiotherapy’, ‘patterns of practice’, and ‘dose fractionation’.
Titles and abstracts were screened independently by two authors (RM,
LR) to determine relevant articles to be obtained for full-text review.
Articles met inclusion criteria if they were primary research
studies with either a primary or secondary goal of investigating
different palliative radiation therapy dose fractionation schedules
for treatment courses to bone metastases. The data must have
been collected from veriﬁed patient databases. Abstracts were also
included if they were deemed relevant and provided sufﬁcient
information regarding RT regime. Although the focus was patterns
of practice in the past twenty years (1994–2014), articles that
analyzed data beginning before this time period but continuing
past 1994 were included. Exclusion criteria were articles that
investigated patient preference or those that surveyed physicians
using hypothetical scenarios. Full text articles were again screened
independently by two authors (RM, LR). If disagreement existed, a
discussion ensued until a consensus was obtained.
The prevalence of various fractionation schedules was
extracted from each of the ﬁnal articles included in the review.
Other relevant information, such as signiﬁcant predictive factors
for the use of single fraction radiation therapy, changes in the
prevalence of fractionation schedules over time, and types of bone
metastases irradiated, was also included. The ﬂow chart describing
the inclusion process for the articles can be found in Fig. 1.
3. Results
Of a total of 613 articles generated by the search, 26 met the
inclusion criteria. The articles were published from 2003 to 2014:
11 were Canadian [14–24], 8 were European [25–32], 6 were
American [33–38], and 1 was Australian [39]. The use of SFRT to
treat bone metastases was widely variable among the studies
examined, ranging from as low as 3.3% to as high as 75% [36,39].
Table 1 features the dose fractionation schedules prescribed in all
studies, arranged by region and study period.
3.1. Canada
Eleven Canadian studies that reported on dose fractionation in
the treatment of bone metastases were published between 1994
and 2014, with data ranging from 1984 to 2011. The study with the
earliest cohort included 44,223 irradiated bone metastases treated
between 1984 and 2001 [14]. Thirty four percent of the RT courses
were SFRT. The authors also reported a general increase in the
prescription of SFRT over time, with 27.2% of patients treated with
SFRT in 1984–1986 increasing to 35.4% of patients treated with
SFRT from 1999 to 2001 [14]. A Canadian study published by
Sutton et al. [15] investigated a similar cohort of irradiated bone
metastases (1984–2004), but rather looked at RT schedules pre-
scribed within the last two years of life. Of the 236,078 bone
metastases irradiated, 30% were treated with SFRT. The authors
did not report on speciﬁc changes in SFRT, but did mention that it
was more frequently prescribed in the latter half of the time
period [15]. Another recent abstract was published by Ashworth
et al. [24], which updated the previous cohorts to include 97,150
patients who received 186,694 palliative RT courses to bone from
1984 to 2012. Over the total study period, SFRT was prescribed for
41.3% of RT courses. The prevalence of SFRT was found to increase
from 39% in 1999–2003 to 58% in 2006, then decrease to 42% in
2009–2012.
Danjoux et al. [16] investigated a cohort of patients treated
between 1996 and 2003. Of a total 2989 RT courses to bone, 45%
were treated with SFRT. These authors did not comment on any
change in prescription over time. Similar cohorts were investi-
gated by Haddad et al. [17] and Bradley et al. [18], who investi-
gated RT courses to bone delivered from 1998 to 2002 and 1999 to
2005, respectively. Haddad et al. [17] reported that an average 32%
of 882 RT courses to bone were prescribed SFRT over the study
period. The authors also reported a general decrease in the
prescription of SFRT over time, from 37% in 1998 to 28% in 2002.
A much higher rate was prescribed to patients included in the
study by Bradley et al. [18], with 65% of 965 RT courses to bone
treated with SFRT. Contrary to Haddad et al., Bradley et al. [18]
found an increase in the prescription of SFRT, from 51% in 1999 to
66% in 2005. Of note, these authors speciﬁed that the cohort only
included uncomplicated bone metastases, whereas Haddad et al.
[17] did not specify the type of bone metastases treated. Wu et al.
[20] investigated 1354 bone metastases irradiated between 2003
and 2005. Single fraction radiation therapy was prescribed in 57%
and 33% of patients who were treated in rapid access clinics and
regular clinics, respectively. These authors did not report on a
change in SFRT prescription over time.
Naidoo et al. [19] investigated a group of 7426 patients referred
for RT to bone metastases from 2000 to 2010. Of these patients,
35% were prescribed SFRT. Again, these authors did not specify
whether there was any change in the prescription over time.
Potter et al. [22] conducted a study with 422 RT to bone
metastases treated from 2007 to 2008. The authors differentiated
intent to treat and reported that, of 137 patients with uncompli-
cated bone pain, 48.9% were treated with SFRT.
The most recent cohorts investigated were those by Thavarajah
et al. [21] and Olson et al. [23], from 2005 to 2012 and 2007 to
2011, respectively. Thavarajah et al. [21] included 2549 RT to bone
metastases, of which 65% were prescribed SFRT. These authors
stated that there was no signiﬁcant change in the prescription ofFig. 1. Flow of article inclusion and exclusion process.
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Table 1
Pattern of practice in radiation doses in the treatment of bone metastases.
First author
(year)
Region Time period Number of RT courses delivered Fractionation schedule Ref.
Kong (2007) Canada 1984–2001 44,223 RT courses to bone 34.4% of RT courses were SFRT [14]
Sutton (2006) Canada 1984–2004 Patients who died of cancer between 1984–2004; 236,078 RT courses to
bone delivered with palliative intent
In last 2 years of life: 30% were SFRT, 44% were ﬁve fractions, 11% were 10 fractions [15]
Ashworth
(2014)
Canada 1984–2012 186,694 Palliative RT courses to bone 41.3% of RT courses were SFRT [24]
Danjoux
(2006)
Canada 1996–2003 2989 RT courses to bone Single 8-Gy fraction in 45%, 20 Gy in ﬁve fractions in 42%, 30 Gy in 10 fractions in 4% [16]
Haddad
(2005)
Canada 1998–2002 882 RT courses to bone 32% of courses were SFRT [17]
Bradley
(2008)
Canada 1999–2005 965 RT courses to bone 65% of patients received SFRT [18]
Naidoo (2011) Canada 2000–2010 17,682 Patients, 42% of which were referred for bone metastases 20 Gy/5 fractions was most common, used to treat 59% of bone metastases SFRT used to treat bone
metastases in 35% of patients
[19]
Wu (2010) Canada 2003–2005 1354 RT courses to bone SFRT was prescribed in 57% of patients who went to rapid access clinic and 33% of patients who
went to regular care
[20]
Thavarajah
(2013)
Canada 2005–2012 2549 Courses of RT to patients with bone metastases 65% of RT courses were SFRT [21]
Potter (2009) Canada 2007–2008 422 RT courses to bone metastases in 389 patients Of 137 patients with uncomplicated bone pain, 48.9% were treated with SFRT [22]
Olson (2014) Canada 2007–2011 16,898 Total courses of RT to 8601 patients 49.2% SFRT; More than 10 fractions were prescribed to only 0.2% of patients [23]
Foro Arnalot
(2010)
Spain 1990–2009 3042 Palliative treatments, 78.14% of which were to bone 46.85% of courses were SFRT from 1990 to 1996, 49.25% were SFRT from 1999 to 2009 [25]
Szostakiewicz
(2004)
Poland 1995–2002 1165 Patients irradiated to 1754 bone metastases 19% of patients treated with SFRT [26]
Laughsand
(2013)
Norway 1997–2007 Patients treated with either 8 Gy/1 fraction or 30 Gy/10 fractions to
bone metastases; 14,380 RT courses to bone metastases total
SFRT delivered to 31.3% of patients [27]
Santacaterina
(2004)
Italy 2000 325 Patients treated to 458 bone metastases 257 (79%) of patients were treated with MFRT (30 Gy/10 fractions) [28]
Bhalla (2012) United
Kingdom
2000 and 2006 120 Patients per year who received palliative radiation therapy to bone
metastases
SFRT was prescribed in 42% of patients in 2000 and 40% in 2006 [29]
Moller (2003) Sweden Sept–Dec 2001 A total of 1144 irradiated sites of bone metastases SFRT used in 37% of treatment sites [30]
Williams
(2006)
United
Kingdom
One week,
starting Sept 29,
2003
Palliative radiotherapy given to 43% of 2498 patients (exact number for
bone metastases not provided)
SFRT was the most common prescription, followed by 20 Gy in 5 fractions [32]
van Oorschot
(2011)
Germany 1 month in 2008 62 Patients were treated to bone metastases Of 18 patients who were treated to bone metastases with the intent of pain relief, only 2 received
SFRT. Most common fractionation was 30 Gy/10 fractions for bone metastases
[31]
Chen (2013) United
States
2003–2005 194 Patients with lung cancer who received radiation treatment to bone 50% Received 6–10 fractions, 20% received ﬁve fractions or lower, 6% received a single fraction [33]
Beriwal (2012) United
States
2003–2010 7905 Sites of bone metastases treated with RT 37.8% of patients received 1–5 fractions. Single-fraction was chosen for palliation in 13.5% of cases
at academic centers, and 3.9% at community centers
[34]
Bekelman
(2013)
United
States
2006–2009 3050 Patients treated with palliative RT to bone 3.3% were treated with SFRT. When previously documented complicated bone metastases were
excluded, 3.8% of 2028 patients were treated with SFRT
[36]
Bekelman
(2014)
United
States
2006–2012 5160 Patients treated with palliative RT to bone 4.0% were treated with SFRT. When previously documented complicated bone metastases were
excluded, 4.1% of 4006 patients were treated with SFRT
[38]
Ellsworth
(2014)
United
States
2007–2012 339 Patients whose ﬁnal RT was for bone metastases 8% Received SFRT 83% of patients were prescribed less than or equal to 10 fractions [37]
Hess (2012) United
States
2008–2009 207 and 213 breast and prostate cancer patients treated with palliative
RT to bone
Majority of patients received at least 10 fractions [35]
Holt (2010) Australia May–October
2005
77 and 207 RT courses for bone metastases at the rapid response clinic
and regular care, respectively
75% and 58% of patients were treated with SFRT to bone at the rapid response clinic and regular
care, respectively
[39]
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SFRT over the study period. Olson et al. [23] examined 16,898 total
courses of RT to bone metastases. They reported that an average of
49.2% of irradiated bone metastases received SFRT and that the
prescription of SFRT declined slightly over the study period.
3.2. Europe
European studies were very heterogeneous in the prescription
of SFRT, with Central and Southern European countries [26,28,31]
generally prescribing a lower proportion of SFRT and Northern and
Western European countries [25,27,29,30,32] prescribing a greater
proportion. A Polish study examined 1754 irradiated bone metas-
tases from 1995 to 2002, of which 19% were treated with SFRT
[26]. These authors also reported that the proportion of patients
treated with SFRT was greater in 2001–2002 when compared to
earlier in the study period. A study conducted in Italian cancer
centers by Santacaterina et al. [28] reported a comparable pre-
valence of SFRT, prescribed for 21% of 458 bone metastases treated
in 2000. The lowest rate of SFRT prescription was reported by
German authors who conducted a one month audit of a cancer
center in 2008 [31]. Of the 18 patients treated for painful bone
metastases, 2 (11%) were prescribed SFRT. Both the Italian and
German studies did not report on a change in prescription of SFRT
due to the narrow time period examined.
Western and Northern European countries generally reported a
much greater proportion of bone metastases irradiated with SFRT
compared to other European countries, with rates ranging from
31% to 49%. A study conducted in Spain explored a cohort of
patients treated to 2377 bone metastases from 1990 to 1996 and
1999 to 2009 [25]. SFRT was prescribed to 46.9% and 49.3% of
patients, respectively. A Norwegian study investigated a similar
cohort of patients treated to 14,380 bone metastases between
1997 and 2007 [27]. An average of 31.3% of RT courses delivered
over this time period were SFRT. A very large increase in the
proportion of SFRT prescribed was observed in this study, rising
from 16.1% of patients in 1997 to 40.5% of patients in 2007.
A comparable proportion of SFRT was observed in a Swedish cohort
of patients, treated to 1144 bone metastases between September
and December 2001 [30]. In this population, SFRT was prescribed
to 37% of bone metastases. The prescription of SFRT was slightly
greater in a United Kingdom study, which examined 120 patients
per year between 2000 and 2006 who were treated for bone
metastases [29]. SFRT was prescribed in 35% of RT courses. The
authors speciﬁed that no signiﬁcant change in SFRT prevalence
was observed over the study period. Another study was conducted
in the United Kingdom with data collected for one week, begin-
ning September 29, 2003 [32]. Although exact data is not available,
the authors state that the most common prescription in the
palliation of bone metastases was a single 8 Gy, followed by
20 Gy in ﬁve fractions. The least common schedule of use was
30 Gy delivered in 10 fractions.
3.3. United States
SFRT was the least commonly used in the United States. An
American study with a small cohort of patients (n¼194) with a
lung primary and treated to bone metastases from 2003 to 2005
reported that 6% of patients received SFRT [33]. These authors did
not specify whether or not a change in the prescription of SFRT
was observed. A much larger cohort of patients with over 7000
bone metastases irradiated between 2003 and 2010 was investi-
gated by Beriwal et al. [34]. The prevalence of SFRT in this
population was 3.9% and 13.5% at community and academic
centers, respectively. Although the authors did not include speciﬁc
numerical values, they stated that the total number of delivered
fractions decreased gradually over the study period.
Bekelman et al. [36] investigated prostate cancer patients who
were treated with palliative RT to bone metastases between
January 2006 and December 2009. A total of 3050 patients were
included, of which 3.3% were prescribed SFRT and 50.3% were
prescribed greater than 10 fractions. When adjusted to exclude
patients with previously complicating events (i.e., pathologic
fractures, spinal cord compression, etc.), the prevalence of SFRT
increased slightly to 3.8% [36]. Bekelman et al. [38] also published
an abstract in 2014 that expanded on the previous study and
included patients with breast, prostate, lung, kidney, colon and
bladder cancer who were treated with palliative RT to bone from
2006 to 2012. A similar prevalence of SFRT was prescribed for this
cohort of patients, at 4.0%. Again, when restricted to patients who
experienced no prior complicating event, the prevalence increased
by only 0.1% [38]. A study conducted by Hess et al. [35] investi-
gated patients with breast and prostate cancer primaries, who
were treated to bone metastases in the United States between July
2008 and December 2009. Similar to the previous American
studies, these authors reported that the majority of patients
received at least 10 fractions. Contrastingly, Ellsworth et al. [37]
studied 339 patients who received RT for bone metastases
between April 2007 and July 2012, of which the majority of
patients received equal to or less than 10 fractions. The prevalence
of SFRT was also approximately double that which has been
reported in previous US studies (8%) [37].
3.4. Australia
Holt et al. [39] published the only Australian study investigat-
ing patterns of practice in the delivery of RT to bone metastases.
These authors examined RT courses delivered to bone metastases
between May and October 2005 at a rapid response clinic and
regular care center. They reported the greatest prevalence of SFRT
among all studies; 75% and 58% of patients treated were pre-
scribed SFRT in the rapid response clinic (n¼77) and regular care
center (n¼207), respectively [39].
3.5. Factors associated with SFRT
Sixteen of the 26 included studies reported on predictive factors
for the use of SFRT [14,17,18,21–24,26,27,29,33,34,36–39]. The most
common signiﬁcant predictive factors were increased age
[14,17,18,21,24,27], poor patient prognosis [14,17,18,23,24,27,36,38],
irradiation to non-spine locations [14,18,23,24,26,34], and patients
with primary prostate cancer [18,21,23,27]. SFRT was also more likely
to be prescribed to those living a greater distance from the treatment
center [14,18,24,27], those with a lung primary [26,27,29], when the
prescribing physicians had greater experience [18,21,23], and when
the treatment center was an academic as opposed to community
practice [20,34]. The signiﬁcance of some factors, such as the age of
patients, treatment site, and physician experience, was contradictory
as they were reported in two studies to not be signiﬁcant [29,34,37].
Table 2 provides a detailed summary of the predictive factors of SFRT
found in each article.
4. Discussion
The majority of advanced cancer patients will develop bone
metastases at some point in their illness [1,2]. As such, optimal
management of bone metastases is central to patient care. Optimal
management involves considering all risks and costs of treatment
with appropriate goals of care in mind. In advanced cancer
patients, these goals of care are palliative in intent and should
be centered on improving pain and QOL [3].
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A recent systematic review on randomized control trials
investigating the efﬁcacy of various dose fractionation schedules
was published by Chow et al. in 2012 [40]. The authors identiﬁed
25 RCTs and concluded that both SFRT and MFRT were equally
efﬁcacious in providing pain relief. Retreatment rates were greater
in patients treated with a single fraction; however, this may be a
product of the increased likelihood for physicians to offer re-
irradiation to patients who have been treated with lower overall
doses [40]. Other meta-analyses [41,42] have been previously
published, concluding similar results to Chow et al. Different trials
have been conducted to evaluate dose fractionation schedules in
complicated bone metastases, such as those presenting with
neuropathic pain, at risk of fracture, and spinal cord compression.
In these circumstances, multiple fractions may have increased
efﬁcacy, especially in those with greater prognosis [8,9,43].
As expected, treatments of a single fraction are more cost
effective compared to multiple treatments. Konski et al. [44]
conducted an economic analysis on the Radiation Therapy and
Oncology Group (RTOG) 97-14 trial, which investigated the efﬁ-
cacy of single versus multiple fractions in pain relief caused by
bone metastases from breast and prostate cancer. The authors
concluded that, even with the potential for greater re-treatments
with SFRT, a single treatment is still more cost effective when
compared to multiple. This study did not factor in patient cost of
travel and lost productivity, which would further conﬁrm SFRT as
cost effective as less patient visits are required [44]. Findings were
similar in a study by van den Hout et al. [45], who found that the
cost of SFRT and MFRT was $2438 and $3311, respectively. These
ﬁgures include potential re-treatments in both groups. When the
authors included societal costs, the estimated expenses increased
Table 2
Changes of SFRT and its associations.
First author
(year)
Region Time
period
Change in SFRT prescription practice over study period Associations with SFRT Ref.
Kong (2007) Canada 1984–2001 1984–1986: 27.2% Increased age, poorer prognosis, non-spine
locations, greater distance to cancer center
[14]
1987–1992: 40.3%
1993–1998: 31.6%
1999–2001: 35.4%
Sutton (2006) Canada 1984–2004 SFRT was used more frequently in latter half of study period NA [15]
Ashworth
(2014)
Canada 1984–2012 1999–2003: 39% Non-spine locations, increased age, poorer
prognosis, greater distance to cancer center
[24]
2006: 58%
2009–2012: 42%
Haddad
(2005)
Canada 1998–2002 1998: 37% Increased age, greater weight loss, poorer
prognosis
[17]
1990: 30%
2000: 43%
2001: 26%
2002: 28%
Bradley
(2008)
Canada 1999–2005 51% in 1999, to 70% in 2001, to 71% in 2004 and 66% in 2005 Increased age, prostate primary, poor
performance status, greater distance from cancer
center, treatment to limbs, hips, pelvis, and ribs,
and increasing physician experience
[18]
Potter (2009) Canada 2007–2008 NA Uncomplicated bone metastases [22]
Thavarajah
(2013)
Canada 2005–2012 No signiﬁcant change over the study period Increased age, prostate cancer, patients receiving
re-irradiation, physicians who were trained prior
to 1990; most common reasons for MFRT included
spinal cord compression, postoperative RT,
and impending fracture
[21]
Olson (2014) Canada 2007–2011 Declined from 50.5% to 48.0% Those with hematological and prostate cancer,
treatment to ribs and extremity, poor prognosis,
increasing physician experience and site of
training,
and re-irradiation
[23]
Szostakiewicz
(2004)
Poland 1995–2002 The proportion of patients treated with SFRT was greater
in 2001–2002 compared to previous periods
Used most commonly for ribs, long bones,
and from lung and breast cancer
[26]
Foro Arnalot
(2010)
Spain 1990–2009 Increase in number of SFRT and number of fractions with 20 Gy/5
Similar instances of 30 Gy/10
NA [25]
Laughsand
(2013)
Norway 1997–2007 Patients treated with SFRT rose from 16.1% in 1997 to 40.5% in 2007 Lung and prostate cancer, increased age,
poorer prognosis, greater living distance
from treatment center
[27]
Bhalla (2012) United
Kingdom
2000 and
2006
No signiﬁcant change over the study period Age and treatment site were not signiﬁcant
predictors of fractionation choice; patients
with lung cancer were more likely to receive SFRT
[29]
Chen (2013) United
States
2003–2005 NA Patients treated in integrated networks received
an average 3.4 fewer fractions and 4.0 Gy less
[33]
Beriwal (2012) United
States
2003–2010 Number of fractions decreased gradually over time Academic practices were more likely to treat
with fewer fractions. Treatment of spine and
extremity metastatic sites were associated
with greater fractions Experience of oncologist
was not predictive of RT regime
[34]
Bekelman
(2013)
United
States
2006–2009 NA Poorer prognosis [36]
Bekelman
(2014)
United
States
2006–2012 No signiﬁcant difference by year No signiﬁcant difference by diagnosis [38]
Ellsworth
(2014)
United
States
2007–2012 No signiﬁcant difference in fractions prescribed before and after
publication of 2011 ASTRO guidelines
Irradiated site not predictive of SFRT [37]
Holt (2010) Australia May–Oct
2005
NA Treatment in the rapid response clinic [39]
R. McDonald et al. / Journal of Bone Oncology 3 (2014) 96–102100
to $4700 for SFRT and $6453 for MFRT [45]. Again, this study
clearly favours single fraction treatments as more cost effective
when compared to protracted radiotherapy courses.
In light of the various published randomized control trials and
meta-analyses, guidelines regarding appropriate dose fractiona-
tion schedules have been released by several cancer organizations.
Cancer Care Ontario (CCO) is a predominant cancer organization in
Ontario, Canada, and went through an extensive process with
radiation oncologists across the province to develop a guideline for
appropriate dose fractionation schedules. The ultimate recommen-
dation of this 2004 guideline was the use of a single 8 Gy RT course
to palliate symptomatic uncomplicated bone metastases [46]. The
American College of Radiology (ACR) most recently in 2009, on
recommendation of an expert panel, stated that a single fraction
was just as efﬁcacious as multiple fractions in the relief of
uncomplicated bone pain. Furthermore, they concluded that SFRT
is likely more desirable in patients with poor prognosis and that
SFRT is more cost effective when compared to MFRT [11]. A
similar evidence based guideline was released in 2011 by ASTRO
and reinforced the recommendation that a single 8 Gy be used
to palliate uncomplicated bone metastases [10]. Overall,
although there has been some increase in the prescription of
SFRT seen in this review, the guidelines and meta-analyses have
not had a signiﬁcant impact on international patterns of practice
to date.
Our review found that American radiation oncologists demon-
strated the most unwillingness to adhere to guidelines, with the
lowest prescription of SFRT compared to all other countries
worldwide. The prevalence of SFRT was as low as 3.3% in this
country. European and Canadian physicians also demonstrated
reluctance, although generally less-so than their American coun-
terparts. Single fraction RT courses were prescribed to approxi-
mately 20–50% of patients within these regions. The single study
published in Australia in 2005 showed that Australian radiation
oncologists, particularly those in the rapid access clinic, were the
most consistent with recommendations and had the highest
prevalence of SFRT prescription (up to 75%).
It has been speculated that the geographical variation among
radiotherapy prescription is a function of the respective healthcare
systems within each region. If physicians receive greater reimbur-
sement for multiple fractions compared to a single fraction, they
will likely have greater willingness to ignore guidelines and
prescribe a longer course. Lievens et al. [47] conﬁrmed this
hypothesis in a study published in 2000. The authors investigated
reimbursement methods and their relation to the delivery of
different radiotherapy dose fractionation schedules in Western
Europe. Payment methods included case payment, where a
department is reimbursed per patient or per case, and fee-for-
service, where each individual service performed (i.e., planning,
ﬁxation, treatment) is reimbursed separately [47]. The authors
found that countries that employ a case payment method of
remuneration (Spain, Netherlands, and the United Kingdom) also
more frequently prescribe SFRT. In contrast, countries such as
Germany that reimburse physicians using a fee-for-service method
have a greater prescription of MFRT [47]. These results are
consistent with those found in our review. The privately funded
health care system most prevalent in the United States might also
explain the increased prescription of MFRT; radiation oncologists
will be paid more by private insurance companies for prescribing
protracted courses of treatment.
The international under-prescription of SFRT may also be
related to inadequate knowledge translation and communication;
if physicians are unaware of the most recent evidence for various
dose fractionation schedules, patients will not be receiving those
recommended treatments [48]. In this way, it is crucial that the
dissemination of knowledge is a priority among all physicians and
cancer organizations. It is only through this that all patients will be
able to receive the best standard of care.
Many of the studies included in this literature review are
limited in that they do not differentiate the fractionation schedules
or bone metastases by the intent of treatment. This poses difﬁculty
because SFRT is not indicated in all cases of bone metastases, but
rather only in the majority of uncomplicated cases. In patients
with neuropathic pain, pathologic fractures, and spinal cord
compression for example, more protracted courses of radiotherapy
may be more effective. Therefore, the studies likely do not
represent the true amount of physicians who are prescribing to
evidence-based guidelines; regions where the prescription of SFRT
is low may just be those with a greater incidence of patients
presenting with complicated bone metastases. Future trials should
incorporate intent to treat as an evaluable factor in RT. This will
allow for the adequate assessment of clinician adherence to
guidelines.
Furthermore, this review focuses only on conventional radia-
tion therapy. With the advent of new technology, guidelines and
practice must be continuously revisited and adjusted appropri-
ately. Stereotactic body radiation therapy (SBRT), which allows for
the delivery of radical doses of radiation to oligometastatic disease
with great precision [49], is particularly useful for patients with
prolonged survival, radioresistant tumors, or those receiving re-
irradiation [50–52]. Guidelines for practice for SBRT are much
different than those for conventional radiotherapy. Future studies
investigating patterns of practice in this setting would be
beneﬁcial.
5. Conclusions
Despite the publication of many randomized control trials,
meta-analyses, and evidence-based practice guidelines, all recom-
mending the prescription of SFRT for pain relief of uncomplicated
bone metastases, there remains an international unwillingness to
conform to this practice. This may be related to the method of
remuneration for radiation oncologists or perhaps a lack of
informed decision making on part of the physician. Knowledge
dissemination is a critical component of research to ensure that
patients are receiving the most recent best standard of care. Future
trials should ensure that a differentiation is made between
uncomplicated and complicated bone metastases, as these classi-
ﬁcations have signiﬁcant impact on dose fractionation prescribed.
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